Atropos Health, a company that translates real-world clinical data into real-world evidence, announced a partnership with Databricks, a data intelligence and AI provider.
By expanding on the Databricks Data Intelligence Platform and leveraging delta sharing, Atropos Health aims to enable clinicians and researchers to create actionable insights to increase drug discoveries and reduce the time from symptom to treatment.
In a statement, Atropos Health said it employs delta sharing to access and link datasets across its network, which contains more than 300 million patient records, including oncology data.
Delta sharing is Databricks’ open-source approach that allows customers to share live data across platforms, clouds and regions with security and governance.
Atropos Health and Databricks aim to unearth “new opportunities in healthcare and life sciences” by offering GENEVA OS (generative evidence acceleration operating system) and the Atropos evidence network, combining Atropos Health’s real-world evidence with Databricks’ data intelligence services.
Michael Sanky, vice president of Healthcare and Life Sciences GTM at Databricks, said that his company is invested in bringing technology solutions to market for every industry, including working with partners like Atropos Health.
“Atropos Health exemplifies the transformative potential of building on Databricks, and it’s incredible to watch its adoption among healthcare and life sciences organizations who are excited to harness the full power of their data.”
THE LARGER TREND
In April, Atropos entered into a strategic partnership with Ontada, a McKesson business involved in community oncology.
Ontada is linked to The US Oncology Network, a wholly owned subsidiary of McKesson, which delivers real-time data, insights and research on how cancer is treated in a community.
The collaboration aimed to strengthen the use cases for clinicians, researchers and healthcare leaders to design care protocols, promote precision medicine and create new treatments in oncology.
In February, Atropos entered into a partnership with Emory Healthcare. The health system piloted a program that aimed to advance patient care by allowing clinical questions to be answered in real-time using Atropos’ platform.
The Atropos Evidence Network allows Emory users to run studies on national datasets and local Emory data.
Clinicians can also use Atropos’ Green Button to access real-world evidence, generating results through supervised evidence development or a fully automated generative AI version (ChatRWD).
In January, Atropos partnered with xCures to leverage RWE-based insights to support patient care, and Atropos partnered with Merck to generate RWE, replicate studies and produce rapid insights and analytics based on real-world data.
Last year, Databricks hit a $62 billion valuation after raising $10 billion in a Series J funding round. The company has raised a total of $8.6 billion.
Thrive Capital, Andreessen Horowitz, GIC, WCM Investment Management, Insight Partners, and DST Global co-led the round, with participation from existing investors Ontario Teachers’ Pension Plan and new investors MGX, ICONIQ Growth, Wellington Management and Sands Capital.
Credit: Source link
